%0 Journal Article
%T Assessment of self-injection experience in patients with rheumatoid arthritis: psychometric validation of the Self-Injection Assessment Questionnaire (SIAQ)
%A Dorothy Keininger
%A Geoffroy Coteur
%J Health and Quality of Life Outcomes
%D 2011
%I BioMed Central
%R 10.1186/1477-7525-9-2
%X The construct validity and reliability of the SIAQ were tested in patients with rheumatoid arthritis who volunteered to inject certolizumab pegol using a standard syringe during an open-label multinational extension trial of the long-term safety and efficacy of this drug. The SIAQ PRE module was self-completed before the first self-injection, and the POST module was self-completed following each of three fortnightly self-injections.Ninety-seven patients completed the SIAQ. All items correlated well with their respective domains in confirmatory factor analysis. As predicted, compared with other participants, patients with very low scores (less than 3 out of 10) in PRE causal domains (Feelings about injections and Self-confidence) were significantly less satisfied with their first self-injection, as were patients with a very low score in any POST causal domain (Self-confidence, Feelings about injections, Injection-site reactions and Ease of use), demonstrating known-groups validity. Causal domain scores generally correlated most strongly with the Satisfaction with self-injection domain, supporting convergent validity. The SIAQ demonstrated internal consistency and reproducibility; Cronbach's ¦Á and the test-retest coefficient were > 0.70 for all domains. Sensitivity and responsiveness were also shown, where measurable. Each language version showed structural validity.The SIAQ was demonstrated to be a valid, reliable tool in patients with rheumatoid arthritis.Rheumatoid arthritis (RA) is a chronic autoimmune disease that is associated with increased morbidity and mortality, and requires long-term treatment [1,2]. The disease leads to pain, fatigue and impairment in physical function, which limit activities and result in a significant decline in health-related quality of life (HRQoL) [3]. Disease-modifying anti-rheumatic drugs (DMARDs) have been demonstrated to improve physical function and HRQoL [4]. Anti-tumour necrosis factor drugs (anti-TNFs) are biologic DMARDs that
%U http://www.hqlo.com/content/9/1/2